Notal Vision News
23 articles
בינה מלאכותית בשירות רפואת העיניים: "פתרונות טכנולוגיים ברמה עולמית"
Israeli start-up NOTAL VISION, which provides patient-focused digital health services for remote monitoring, has won the Roche for a Better Future program. The companys technology expands the monitoring of retinal diseases from the clinic to the home, providing ophthalmologists with remote diagnostic tools to support their patients treatment. The technology allows for self-monitoring and home diagnosis, data analysis using artificial intelligence, and a customer support system. The company will begin clinical research at Beilinson Hospital with the support of Roche Israel.
PartnersInvestment
11 promising new technologies to help us see better - ISRAEL21c
The article discusses various Israeli companies that are developing innovative solutions to improve visual health. OrCam Technologies offers AI-driven reading aids for people with blindness or low vision. CorNeat Vision has developed a non-degradable tissue-integrating material technology for corneally blind people and those suffering from glaucoma. Notal Vision provides remote monitoring services for vision testing. Samsara Vision has developed an Implantable Miniature Telescope (IMT) for individuals with advanced, irreversible AMD. AEYE has developed a desktop system for diagnosing diabetic retinopathy. EyeYon Medical has developed cornea-focused sight-saving solutions. NovaSight offers eye-tracking-based solutions for early vision disorders. EyeCan is developing a smart headband for visually impaired swimmers. DeepOptics is developing personalized, connected glasses that dynamically correct vision impairment. TopoSpeech is developing a sensory substitution device for spatial information. Orasis Pharmaceuticals is developing corrective eye drops for treating presbyopia.
CustomersInvestmentExpand
Notal Vision Reports Publication of First U.S. Home OCT Study Results
Notal Vision, a digital healthcare provider, has announced the results of the first U.S.-based study with its investigational home-based optical coherence tomography (OCT) platform. The study found over 95% agreement when comparing retinal fluid detection capability, a primary marker for treatment guidance, between Notal Home OCT and in-office OCT. The results are significant for the management of patients suffering from wet age-related macular degeneration (AMD), the leading cause of blindness in the United States. The study also demonstrated the ease of use and convenience of daily imaging with the Notal Home OCT device.
CustomersPartners
Ophthalmic monitoring co Notal Vision raises $60m
Notal Vision, an ophthalmic home monitoring services provider, has closed a Series D financing round of up to $60 million. The investment will support the commercial growth of the companys current service, the ForeseeHome AMD Monitoring Program, and the marketing strategy for its Home OCT pipeline technology. The funding will also allow Notal Vision to expand its remote patient monitoring services and build referral partnerships with ophthalmologists and optometrists. The company plans to introduce its Home OCT monitoring program for patients with exudative retinal diseases. Notal Vision is positioned to lead the ophthalmic home diagnostic services market and improve outcomes for patients with ocular diseases.
Investment
ForeseeHome AMD home monitoring real-world data analysis demonstrates substantial benefit for patients' vision
Real-world data on the performance of Notal Visions ForeseeHome AMD Monitoring Program, a home-based diagnostic for age-related macular degeneration (AMD), was published in the Journal of Clinical Medicine. The data showed that the use of ForeseeHome provided a significant benefit to patients by helping to detect wet AMD earlier with better visual acuity. The studys principal author, Dr. Allen C. Ho, stated that earlier detection of wet AMD with this FDA-cleared device is a strong predictor of better vision outcomes. The ForeseeHome program, provided by Notal Vision, includes patient engagement, compliance monitoring, and alert generation services. The program resembles the findings of a randomized controlled study and has gained Medicare coverage. Notal Vision is a diagnostic services company that operates the Notal Vision Diagnostic Clinic.
Customers
AsclepiX Therapeutics partners with Notal Vision on Home OCT remote monitoring in DME and AMD clinical trials
Notal Vision will provide AsclepiX Therapeutics with Home OCT monitoring services for their clinical trial program. The technology aims to enrich clinical trial datasets and reduce the burden of frequent office visits for patients with retinal diseases. The Home OCT device will be used by study subjects with diabetic macular edema and wet age-related macular degeneration to perform daily self-imaging of their eyes. The data will be transmitted to the Notal Health Cloud, where an AI-based analyzer will identify and quantify fluid in the eyes. The results will be shared with AsclepiX and the investigators. Notal Visions Home OCT technology has received FDA Breakthrough Device designation and is in the process of obtaining FDA clearance.
Partners
AI-based OCT analysis of AREDS2 10-Y follow-on study demonstrates superior performance over retina specialists
A study published in Ophthalmology shows that Notal Visions OCT Analyzer achieved a higher level of accuracy in detecting retinal fluid in wet age-related macular degeneration (AMD) compared to retina specialists. The study highlights the potential benefit of AI-assisted image review in routine clinical care. Notal Visions home-based OCT technology, which received FDA Breakthrough Device designation, aims to assist physicians in identifying, quantifying, and mapping intra- and subretinal fluid in wet AMD. The company is in the process of obtaining FDA clearance. Notal Visions Home OCT system allows wet AMD patients to perform technician-free OCT testing at home. The Notal OCT Analyzer (NOA) performs automated analysis of the Home OCT scans and generates a report for physicians when a change in disease activity is detected.
Customers
Notal Vision Diagnostic Clinic Implements XIFIN RPM to Improve Claim Accuracy, Timely Reimbursement and Patient Experience
AI-based retinal fluid analytics of serial Notal Vision home OCT images offers insights into retinal disease dynamics
Notal Vision presented longitudinal data on retinal imaging using their home OCT device at a medical meeting. The device, NOTAL-OCT V3.0, is designed to support the management of patients with age-related macular degeneration (AMD). The data showed that the device can track fluid in the retina over time and correlate it with disease status. The home OCT technology allows physicians to assess retreatment intervals and detect retinal fluid as soon as it occurs. Notal Visions home-based OCT pipeline technology has received FDA Breakthrough Device designation and is in the process of obtaining FDA clearance. The company aims to improve vision outcomes and reduce treatment burden through their diagnostic services and AI-enabled analyses of personalized health data.
Customers
CPT codes for home OCT established
Notal Vision, Inc. announced that the American Medical Associations (AMA) CPT Editorial Panel has established three new Category III codes for patient-initiated remote retinal optical coherence tomography (OCT) scans using Notal Visions home-based OCT pipeline technology. The new codes allow for billing for device provision, set-up, patient education, technical support, data analyses, and reports. Notal Visions CEO believes that home-based OCT will be the future of monitoring patients with wet AMD. The companys next focus is proving clinical relevance and providing valuation to Medicare, Medicaid, and payors. Notal Visions home-based OCT pipeline technology received FDA Breakthrough Device designation in 2018 and has the potential to individualize and advance retinal disease management.
CustomersPartners
Israeli healthtech startup Notal Vision secures $25M to provide better methods of detecting age-related macular degeneration
Notal Vision, a healthtech startup focused on advancing eye care, has raised $25 million in funding to support the growth of its current service and further research and development efforts. The funding was led by existing investor Ganot Capital. Notal Vision is developing a comprehensive diagnostic solution for the early detection and monitoring of Age-Related Macular Degeneration (AMD). The companys platform leverages AI-enabled analyses of personalized health data to improve vision outcomes. With the additional investment, Notal Vision aims to expand its sales team and drive deeper adoption of its home diagnostic services. The company is also well-funded to continue developing its Home OCT platform. Notal Vision is uniquely positioned to lead the ophthalmic home diagnostic services market.
InvestmentExpand
Notal Vision Announces Appointment of Dr. Kester Nahen as Chief Executive Officer
Notal Vision has appointed Kester Nahen as Chief Executive Officer to lead the companys next phase of growth. Nahen, who previously served as Chief Commercial Officer, brings extensive experience in the medical device industry. Notal Vision is focused on advancing eye care with precision medicine and extending disease management from the clinic to the home. The companys ForeseeHome and Home OCT diagnostic services programs aim to support patients throughout their journey from early diagnosis to personalized therapeutic management of retinal diseases. With Nahens leadership, Notal Vision aims to continue leading the ophthalmic home diagnostic services market through the development of low-cost medical devices, AI-driven decision support solutions, and a clinical patient engagement platform.
Management Changes
Notal Vision Diagnostic Clinic reports completion of 6 million ForeseeHome AMD home-monitoring tests
Notal Vision, Inc., a company focused on eye care, has celebrated the completion of six million patient tests performed with ForeseeHome, the first FDA-cleared home-monitoring device for patients with intermediate dry Age-related Macular Degeneration (AMD) at risk for developing wet AMD. ForeseeHome uses a patented technology, Preferential Hyperacuity Perimetry® (PHP), that can identify minute changes in the central 14 degrees of visual field before the patient has any visual symptoms. The results are sent to the Notal Vision Diagnostic Clinic (NVDC) via a cloud-based ecosystem. If there is a significant change, the adaptive test will generate an alert which is provided to the patient’s eye doctor by the NVDC.
CustomersExpand
Notal Vision Engages Wasatch Photonics Bringing AI-Enabled Home-Based Optical Coherence Tomography Closer to Market
Notal Vision has achieved a significant milestone in developing a home-based OCT system for monitoring exudative age-related macular degeneration (eAMD) patients. The system includes a patient-operated OCT device that generates images to be analyzed by an AI algorithm. The first U.S. clinical trial for the system began in October 2018. The images produced by the system have been deemed of excellent quality by retina specialists. The FDA has granted the system Breakthrough Device Designation. Notal Vision plans to expand its clinical trial program in 2019. Notal Vision leverages artificial intelligence and a cloud-based platform to connect healthcare providers, its Diagnostic Clinic, and patients for remote management of ophthalmic diseases.
Customers
Notal Vision Announces FDA Grants Breakthrough Device Designation for Pioneering Patient-Operated Home Optical Coherence Tomography (OCT) System
Notal Vision, Ltd., a privately-held ophthalmic diagnostic services company, has received FDAs Breakthrough Device designation for its Home-based Optical Coherence Tomography (OCT) System. The system is an AI-based device for automated identification of intra- and/or subretinal fluid in eyes diagnosed with exudative age-related macular degeneration. The Notal Home OCT is a patient-friendly device that allows eAMD patients to perform OCT testing at home, with immediate notification to retinal specialists if recurrent disease activity is detected. Notal Vision plans to bring the Home OCT System to the market in 2020.
Customers
Notal Vision to Present on Home-based Optical Coherence Tomography at the Upcoming Ophthalmology Innovation Summit in New Orleans
Notal Vision, a privately-held ophthalmic company, will be presenting at the Ophthalmology Innovation Summit. They will be showcasing their Home OCT device in development, which is part of their cloud-based platform for remote diagnostic testing. The device aims to personalize wet AMD management and improve long-term visual acuity maintenance. Notal Vision has established a seamless, cloud-based platform that connects healthcare providers and patients for the detection of ocular diseases. The company was founded by two ophthalmologists and is focused on providing innovative, home-based diagnostic technologies for patients with retinal diseases.
CustomersPartners
News - Eyewire+
The article provides information about Eyewire+ as a source for updates in the ophthalmic field.
BizSpotlight Press Releases - Washington Business Journal
Notal Vision announces new CIO
Notal Vision Ltd. has appointed Roni Amiel as chief information officer to advance the companys cloud-based technology and capabilities. The appointment is seen as a step forward in Notal Visions growth as a pioneer in home-based telemonitoring for ocular diseases. Notal Vision has a cloud-based infrastructure that connects healthcare providers and patients for personalized, home-based detection and monitoring of ocular diseases.
Management Changes
Notal Vision Names Jim Long as Chief Financial Officer
Notal Vision has appointed Jim Long as Chief Financial Officer. Long will be responsible for the companys financial operations and strategy. The appointment is expected to help Notal Vision meet its ambitious growth goals. Long has over 25 years of experience in private healthcare technology and services companies. Notal Vision is a privately-held ophthalmic company that developed ForeseeHome, the first FDA-cleared home-based monitoring system for patients with age-related macular degeneration (AMD). The company focuses on providing innovative, home-based technology solutions for visual health in AMD patients.
Management Changes
Notal Vision Achieves Medicare Coverage For ForeseeHome
Notal Vision, Inc. has announced that its ForeseeHome AMD Monitoring Program is now available for eligible Medicare patients across the U.S. The program is designed for patients with Dry Age-related Macular Degeneration (AMD) who are at high risk of developing Wet AMD. The ForeseeHome program was tested in a National Eye Institute-sponsored study, where it was found to significantly increase early detection of wet AMD. Notal Vision has been working for nearly two years to make this device available to Medicare patients.
CustomersExpand
Notal Vision sets its sights on early detection of AMD
Notal Vision, an Israeli medical technology company, has developed a device called Macular Computerized Psychophysical Test (MCPT) that can detect age-related Macular Degeneration (AMD) more accurately and earlier than the current standard diagnostic. In clinical studies, the MCPT was shown to be more than twice as likely to detect the presence of AMD. The device uses hyperacuity to detect retinal lesions from AMD, allowing for early treatment initiation. Notal Vision has partnered with Carl Zeiss Meditec Inc. for worldwide distribution rights to the device. Sales of the device will begin in the summer.
CustomersPartners
Notal Vision raises $4m from Elron and Innomed
Notal Vision, a developer of medical diagnostic solutions, has successfully completed a $4 million financing round. The companys diagnostic solution is designed to detect age-related macular degeneration. Investors in the round included Elron, InnoMed Ventures, and a group of private investors. Notal Vision recently signed a distribution agreement with Carl Zeiss Meditec. The funding will enable the company to start shipping products and develop future products. Notal Vision aims to become the gold standard in AMD detection and monitoring.
InvestmentPartners
